Investor Profile: Pangaea Ventures — Thesis, Cheque Size & How to Apply

For hard-tech founders, finding startup funding from investors who actually understand the science is half the battle. Pangaea Ventures has been that investor for over two decades. The Vancouver-based venture firm has backed breakthrough innovations in advanced materials, novel chemistry and biology since 2000, with offices in Vancouver, Phoenix and Tokyo. Its edge is a partner network of global materials, chemicals, semiconductor and manufacturing companies that opens pilot facilities, application expertise and first customers to portfolio founders.

Our thesis: hard tech until it is ordinary

Pangaea's central thesis has been consistent since its early cleantech funds: breakthroughs in advanced materials are critical for the continued growth of cleantech, and will be the primary drivers of value for venture-backed exits in the space. The firm's current framing is memorably simple — "Hard tech. Until it's ordinary." — the idea that transformative innovations should become so absorbed into how the world works that nobody calls them breakthroughs anymore.

Sectors and stages: three hard-tech verticals

Pangaea invests across three verticals: Semiconductors & Advanced Manufacturing, Climate & Sustainable Systems, and Human Health & Bioengineering. An early-stage investor typically entering at Series A, it stays close to founders through scale-up, opening doors to customers, strategic partners and co-investors worldwide.

Fund size and cheque size

Pangaea closed its fifth and largest fund in April 2024: a $115 million CAD (approximately $85 million USD) impact fund dedicated to hard-tech solutions for planetary health. The fund runs on a five-year investment period and plans 10 to 12 investments, with roughly half the capital reserved for follow-ons. Typical cheques are $3 million to $5 million per round at Series A, usually as lead or co-lead. Earlier vintages show the same discipline: Pangaea Ventures Fund III announced a first close of $50 million of a $100 million target in 2012, backed by strategic limited partners including Asahi Glass, BASF, Mitsubishi Chemical, SABIC, Solvay and Toyota Tsusho.

Notable portfolio

The portfolio includes Aspect Biosystems, which raised a $115 million Series B for bioprinted tissue therapeutics; CarbonCure, the carbon-utilisation concrete technology; Tidal Vision (chitosan extracted from seafood waste); ChEmpower ($18.7 million Series A, slurry-free semiconductor manufacturing); and pH7 Technologies, which closed a $16 million Series A for clean extraction of critical metals. Other recent bets include Versogen, Kanvas Biosciences, Ardent Process Technologies and Biodel AG.

Partners

The firm's General Partners have included Chris Erickson, Purnesh Seegopaul and Keith Gillard (who joined from BASF Venture Capital at the third fund). The current investment team named on the firm's site and publications includes Andrew Haughian and Principal David Weekes, a chemist who assesses early-stage hard tech across advanced materials, chemistry, engineering and biology.

Programs, credits and perks

Pangaea runs no public accelerator and publishes no formal perks programme — the value-add is the corporate partner network and deep technical diligence. It does publish the annual Hard Tech Report and a Hard Tech Monthly newsletter with portfolio news and team analysis.

How to apply for funding

Pangaea publishes no public application form. Founders are invited to engage through the "For founders" section of pangaeaventures.com, which frames the firm as a long-term partner for teams building hard tech for the planet's big challenges.